These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 22223618

  • 1. Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial.
    Bould H, Wiles N, Potokar J, Cowen P, Nutt DJ, Peters TJ, Lewis G.
    J Psychopharmacol; 2012 May; 26(5):663-9. PubMed ID: 22223618
    [Abstract] [Full Text] [Related]

  • 2. Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial.
    Lewis G, Mulligan J, Wiles N, Cowen P, Craddock N, Ikeda M, Grozeva D, Mason V, Nutt D, Sharp D, Tallon D, Thomas L, O'Donovan MC, Peters TJ.
    Br J Psychiatry; 2011 Jun; 198(6):464-71. PubMed ID: 21263010
    [Abstract] [Full Text] [Related]

  • 3. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.
    Rampello L, Chiechio S, Nicoletti G, Alvano A, Vecchio I, Raffaele R, Malaguarnera M.
    Psychopharmacology (Berl); 2004 Apr; 173(1-2):73-8. PubMed ID: 14685645
    [Abstract] [Full Text] [Related]

  • 4. Severity of depression and response to antidepressants: GENPOD randomised controlled trial.
    Wiles NJ, Mulligan J, Peters TJ, Cowen PJ, Mason V, Nutt D, Sharp D, Tallon D, Thomas L, O'Donovan MC, Lewis G.
    Br J Psychiatry; 2012 Feb; 200(2):130-6. PubMed ID: 22194183
    [Abstract] [Full Text] [Related]

  • 5. Citalopram versus other anti-depressive agents for depression.
    Cipriani A, Purgato M, Furukawa TA, Trespidi C, Imperadore G, Signoretti A, Churchill R, Watanabe N, Barbui C.
    Cochrane Database Syst Rev; 2012 Jul 11; 2012(7):CD006534. PubMed ID: 22786497
    [Abstract] [Full Text] [Related]

  • 6. Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder.
    Aragona M, Bancheri L, Perinelli D, Tarsitani L, Pizzimenti A, Conte A, Inghilleri M.
    Eur J Pain; 2005 Feb 11; 9(1):33-8. PubMed ID: 15629872
    [Abstract] [Full Text] [Related]

  • 7. Are multiple physical symptoms a poor prognostic factor or just a marker of depression severity? Secondary analysis of the GenPod trial.
    Green A, Crawford A, Button KS, Wiles N, Peters TJ, Nutt D, Lewis G.
    J Affect Disord; 2014 Jul 11; 163():40-6. PubMed ID: 24836086
    [Abstract] [Full Text] [Related]

  • 8. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder.
    Juckel G, Pogarell O, Augustin H, Mulert C, Müller-Siecheneder F, Frodl T, Mavrogiorgou P, Hegerl U.
    J Clin Psychiatry; 2007 Aug 11; 68(8):1206-12. PubMed ID: 17854244
    [Abstract] [Full Text] [Related]

  • 9. Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial.
    Gougoulaki M, Lewis G, Nutt DJ, Peters TJ, Wiles NJ, Lewis G.
    J Psychopharmacol; 2021 Aug 11; 35(8):919-927. PubMed ID: 33637001
    [Abstract] [Full Text] [Related]

  • 10. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study.
    Seedat S, van Rheede van Oudtshoorn E, Muller JE, Mohr N, Stein DJ.
    Int Clin Psychopharmacol; 2003 Sep 11; 18(5):279-84. PubMed ID: 12920388
    [Abstract] [Full Text] [Related]

  • 11. Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals.
    Crawford AA, Lewis S, Nutt D, Peters TJ, Cowen P, O'Donovan MC, Wiles N, Lewis G.
    Psychopharmacology (Berl); 2014 Aug 11; 231(15):2921-31. PubMed ID: 24525810
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: a pooled analysis.
    Pjrek E, Konstantinidis A, Assem-Hilger E, Praschak-Rieder N, Willeit M, Kasper S, Winkler D.
    J Psychiatr Res; 2009 May 11; 43(8):792-7. PubMed ID: 19230909
    [Abstract] [Full Text] [Related]

  • 13. Basal prolactin values correlate with response to reboxetine treatment in major depression, but not with response to citalopram.
    Moeller O, Hetzel G, Michael N, Rothermundt M, Arolt V, Erfurth A.
    Neuropsychobiology; 2005 May 11; 51(2):67-71. PubMed ID: 15741746
    [Abstract] [Full Text] [Related]

  • 14. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine.
    Berlanga C, Flores-Ramos M.
    J Affect Disord; 2006 Oct 11; 95(1-3):119-23. PubMed ID: 16782204
    [Abstract] [Full Text] [Related]

  • 15. The effect of serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients.
    Tranter R, Bell D, Gutting P, Harmer C, Healy D, Anderson IM.
    J Affect Disord; 2009 Nov 11; 118(1-3):87-93. PubMed ID: 19250683
    [Abstract] [Full Text] [Related]

  • 16. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment.
    McCabe C, Mishor Z, Cowen PJ, Harmer CJ.
    Biol Psychiatry; 2010 Mar 01; 67(5):439-45. PubMed ID: 20034615
    [Abstract] [Full Text] [Related]

  • 17. Reboxetine plus citalopram for refractory depression not responding to venlafaxine: possible mechanisms.
    Dursun SM, Devarajan S.
    Psychopharmacology (Berl); 2001 Feb 01; 153(4):497-8. PubMed ID: 11243498
    [No Abstract] [Full Text] [Related]

  • 18. Is there a role for a pure noradrenergic drug in the treatment of depression?
    Montgomery SA.
    Eur Neuropsychopharmacol; 1997 Apr 01; 7 Suppl 1():S3-9; discussion S71-3. PubMed ID: 9169305
    [Abstract] [Full Text] [Related]

  • 19. Noradrenaline in basic models of depression.
    Leonard BE.
    Eur Neuropsychopharmacol; 1997 Apr 01; 7 Suppl 1():S11-6; discussion S71-3. PubMed ID: 9169306
    [Abstract] [Full Text] [Related]

  • 20. Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study.
    Grassi L, Biancosino B, Marmai L, Righi R.
    J Clin Psychiatry; 2004 Apr 01; 65(4):515-20. PubMed ID: 15119914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.